@glp-1.bsky.social
November 19, 2024 at 2:33 AM
Reposted
Why #Ozempic should be covered by medicare for #WeightLoss, not just #diabetes treatment, by @drlabos.bsky.social montrealgazette.com/opinion/colu... via @mtlgazette.bsky.social
Christopher Labos: Why Ozempic should be covered by medicare for weight loss
Recent studies reinforce that weight loss is not simply an esthetic consideration. It has very real benefits in terms of preventing disease.
montrealgazette.com
November 15, 2024 at 4:24 PM
Why #Ozempic should be covered by medicare for #WeightLoss, not just #diabetes treatment, by @drlabos.bsky.social montrealgazette.com/opinion/colu... via @mtlgazette.bsky.social
Reposted
GLP-1/GIP agonist therapy is really a revolution in medical care. Hopefully our society will be willing to provide access to all
More data supporting the cardio protective effect of GLP-1 targeted therapy (this time Tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart failure than placebo www.nejm.org/doi/full/10....
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...
www.nejm.org
November 17, 2024 at 5:22 AM
GLP-1/GIP agonist therapy is really a revolution in medical care. Hopefully our society will be willing to provide access to all